Skip to main content
. 2016 Mar 10;18(5):442–448. doi: 10.1016/j.hpb.2016.01.547

Figure 1.

Figure 1

a) Would you ever consider performing an ALPPS procedure in a case where the future liver remnant (FLR) is over 30%?. b) Would you perform the ALPPS procedure for indications other than colorectal liver metastases (CRLM)?. c) Do you routinely recommend that your patients receive systemic neoadjuvant chemotherapy treatment for colorectal liver metastases prior to ALPPS?. d) Do you feel that it is necessary to skeletonize the structures of the hepatoduodenal ligament in the ALPPS procedure?. e) Do you routinely preserve outflow to the middle hepatic vein during stage 1 of a classical ALPPS?. f) Have you observed necrosis of segment 4 at stage 2 of the ALPPS procedure?